Patients with chronic hepatitis C virus (HCV) who were treated with daclatasvir, asunaprevir, and beclabuvir achieved high rates of sustained virologic response (SVR) after 12 weeks, data from two studies have shown. Findings from the studies are published in JAMA.
UNITY-1, an international study, was conducted by researchers from the University of Texas Health Science Center to assess SVR rates in patients receiving twice-daily combination of daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO regimen). SVR was defined as HCV-RNA <25 IU/mL at post-treatment Week 12 (SVR12). SVR12 was seen in 91.3% (379/415) of patients of which 287 were treatment-naive and 92 were treatment-experienced. Virologic failure was seen in 8% of patients.
UNITY-2 was conducted by researchers from the Duke University Medical Center to assess the effectiveness of treatment with daclatasvir, asunaprevir, and beclabuvir in patients who were treatment-naive and treatment-experienced with chronic HCV genotype 1 infection and cirrhosis. Patients were treated with 12 weeks with DCV-TRIO with 24 weeks of follow-up after treatment completion. Patients within each cohort were also randomized to receive weight-based ribavirin (1,000–1,2000mg/day) or matching placebo. In the treatment-naive group, 93% of patients was achieved SVR12 with DCV-TRIO alone, and 98% achieved with ribavirin added. In the treatment-experienced group, SVR12 was achieved by 87% with DCV-TRIO alone, and 93% with ribavirin added.
Researchers conclude that these study results support how all-oral interferon-free regimens have changed the management of hepatitis C.
For more information visit JAMANetwork.com.